“For many cell-based therapies, progress comes from connecting the right pieces at the right moment,” Klein said. “When biology, computation, and the right support come together, you can start to move ...
– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...
Extending human health span by several years is the vision of clock.bio, a biotech startup that is investigating the biology of cellular rejuvenation. The company recently raised $5.3 million in seed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results